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Background: The glucagon and glucagon-like peptide-1 (GLP-1) receptors are important targets for treating type 2
diabetes.
Results: We describe novel glucagon receptor pharmacology, through interaction with the receptor activity-modifying pro-
tein-2 (RAMP2).
Conclusion: RAMP2 regulates both ligand binding and G protein selectivity of the glucagon receptor.
Significance: The effect of RAMP2 should be considered when designing anti-diabetic treatments.
The glucagon and glucagon-like peptide-1 (GLP-1) receptors
play important, opposing roles in regulating blood glucose lev-
els. Consequently, these receptors have been identified as tar-
gets for novel diabetes treatments. However, drugs acting at the
GLP-1 receptor, although having clinical efficacy, have been
associated with severe adverse side-effects, and targeting of the
glucagon receptor has yet to be successful. Here we use a com-
bination of yeast reporter assays and mammalian systems to
provide a more complete understanding of glucagon receptor
signaling, considering the effect of multiple ligands, association
with the receptor-interacting protein receptor activity-modify-
ing protein-2 (RAMP2), and the role of individual G protein
-subunits. We demonstrate that RAMP2 alters both ligand
selectivity and G protein preference of the glucagon receptor.
Importantly, we also uncover novel cross-reactivity of therapeu-
tically usedGLP-1 receptor ligands at the glucagon receptor that
is abolished by RAMP2 interaction. This study reveals the glu-
cagon receptor as a previously unidentified target for GLP-1
receptor agonists and highlights a role for RAMP2 in regulating
its pharmacology. Such previously unrecognized functions of
RAMPs highlight the need to consider all receptor-interacting
proteins in future drug development.
Glucagon, released from pancreatic -cells, is generally con-
sidered as a counterregulatory hormone to insulin (1). It acts via
the glucagon receptor (GCGR),3 a G protein-coupled receptor
(GPCR), to stimulate the release of glucose from the liver into
the blood (2).High blood glucose levels, caused by an imbalance
in plasma levels of insulin and glucagon, are characteristic of
type 2 diabetes. The stimulation of insulin release, via activation
of the glucagon-like peptide-1 (GLP-1) receptor, (a GPCR
closely related to the GCGR) has been the focus of intense
research, resulting in the approval of several drugs (3). Due to
the role that excess GCGR activitymay play in the development
of hyperglycemia, compounds acting at this receptor (to antag-
onize signaling) are also highly sought after (4). However,
despite several years of research with many patents for small
molecule compounds filed (5), there are currently no successful
drugs approved for clinical use.
The GCGR mediates its effects predominantly through the
generation of intracellular cAMP via coupling to heterotri-
meric G proteins containing Gs (6). However, the GCGR can
adopt multiple active conformations, thereby regulating other
downstream pathways, including members of the inhibitory
Gi family (7), which antagonize cAMP production. Distinct
cellular outcomes can therefore be driven, through the stabili-
zation of different receptor conformations (8) by interacting
molecules (including ligands, G proteins, and accessory pro-
teins). Understanding how each of the interactions influences
GCGR signaling could lead to the development of ligands that
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selectively engage therapeutically beneficial pathways, thereby
producing more efficacious drugs with greater specificity and
fewer side effects. To this end, we sought to investigate the
effect of association with a class of interacting proteins, the
receptor activity-modifying proteins (RAMPs), on GCGR
pharmacology. RAMPs have previously been shown to modu-
late the ligand preference for other family B GPCRs (9, 10).
However, no comprehensive study of their role in ligand and G
protein selection has thus far been undertaken.
The three RAMPs (RAMP1, RAMP2, and RAMP3) were first
identified as being essential components of the receptors for
calcitonin gene-related peptide (CGRP) and adrenomedullin
(AM) (11). In addition to this well characterized interaction
with the calcitonin-like-related receptor (CLR), where they are
required to facilitate trafficking to the cell surface, RAMPs also
associate with other family B GPCRs, including the calcitonin
receptor, to modulate ligand and G protein selection (12, 13)
the vasoactive intestinal polypeptide/pituitary AC-activating
peptide 1 (VPAC1) receptor, and the GCGR (9, 10).
Although theGCGR interacts with RAMP2 (9), the impact of
this association on signaling and physiology has not been deter-
mined. Here we report that RAMP2 association significantly
alters the pharmacology of all GCGR ligands. This modulation
is dependent upon the activating ligand and the downstreamG
protein pathway. Furthermore, we show that ligands of the
GLP-1 receptor are able to act as agonists at the GCGR but that
this is abolished by RAMP2 interaction. These results demon-
strate the complex interplay between the ligand, the GCGR,
and the RAMP that alters the signaling bias of the receptor.
Importantly, the study highlights the GCGR as a novel and
potentially significant target for drugs designed to provide ago-
nism at the GLP-1 receptor, which may now be tractable if the
role of RAMP2 is considered. The outcome of our work could
therefore impact upon new or improved drugs to treat type 2
diabetes.
Experimental Procedures
Peptides—Glucagon, oxytomodulin, andGLP-1(7–36) amide
were synthesized by Alta Biosciences (University of Birming-
ham, Birmingham, UK) and prepared as 1 mM stocks in water.
Liraglutide, exenatide, and lixisenatide were supplied by
George Eliot Hospital NHS Trust (Nuneaton, UK). CGRP and
AM were purchased from BACHEM (Bubendorf, Switzerland)
and made to 1 mM stocks in water. The radioligand, [125I]glu-
cagon, was purchased from PerkinElmer Life Sciences. The
GCGR antagonist, des-His1-[Glu9]glucagon(1–29) amide, was
purchased from Tocris (Bristol, UK) and prepared as a 0.1 mM
stock in water. Yeast nitrogen base and yeast extract were pur-
chased from Difco. Flurorescein-di--D-glucopyranoside was
purchased from Invitrogen. All other reagents were purchased
from Sigma-Aldrich.
Constructs and DNA Manipulation—The plasmid for the
generation of direct, in-frame mCherry fusion proteins was
kindly donated by Steve Royale (University ofWarwick). cDNA
constructs of the human GLP-1R (containing an N-terminal
Myc tag) and the human glucagon receptor were donated by
Professor Patrick Sexton (Monash University, Australia) and
Dr. Run Yu (Geffen School of Medicine at UCLA, Los Angeles,
CA), respectively. Constructs for the expression of N-termi-
nally FLAG-tagged human RAMPs were described previously
(10). The cDNA construct containing a Myc-tagged CLR was
provided by Dr. Michel Bouvier (University of Montreal, Can-
ada). RAMP-GFP constructs were purchased from Cambridge
Bioscience (Cambridge Bioscience Ltd., Cambridge, UK). DNA
manipulationswere performed using standardmethods. Oligo-
nucleotides were supplied by Invitrogen. PCR amplification
used FastStart Taq polymerase (Roche Diagnostics, Burgess
Hill, UK). All constructswere sequenced byGATC (GATCBio-
tech, London, UK) prior to use.
Cell Culture and Transfections—Dulbecco’s modified Eagle’s
medium (DMEM) (Invitrogen) supplemented with 10% fetal
calf serum and 2 mM L-glutamine was used to culture human
embryonic kidney (293T) (HEK-293) cells provided by Dr.
Ju¨gen Mu¨ller (University of Warwick) in a humidified 5% CO2,
95% air incubator at 37 °C. Cells were transfectedwith Fugene 6
(Roche Diagnostics) in accordance with the manufacturer’s
instructions using a 1:3 (w/v) DNA/FuGENE ratio. Transfected
cell lines were grown for 48 h prior to assaying. Where
appropriate, pertussis toxin (PTX) (200 ng/ml) was added to
ADP-ribosylate Gi for 16 h prior to assaying, thereby
uncoupling receptor-mediated Gi-dependent inhibition of
cAMP production.
Analysis of Cell Surface Expression by ELISA—Cells were
seeded into 24-well plates coated with poly-D-lysine and tran-
siently transfected with receptors, RAMPs, and vector controls
as appropriate. Following 48 h of growth in supplemented
DMEM, medium was replaced with 3.7% formaldehyde for 15
min. Cells were washed three times with 500 l of phosphate-
buffered saline (PBS) and incubated with 1% BSA in PBS for 45
min to prevent nonspecific antibody binding. To determine
receptor expression, 250 l of primary antibody (mouse anti-
Myc (Fisher), diluted 1:2500 in 1% BSA in PBS) was added for
1 h. RAMP expression was similarly assessed using an anti-
FLAG M2 primary antibody (mouse (Sigma-Aldrich), diluted
1:3500 inPBSwith 1%BSA).Cellswerewashed three timeswith
500l of PBS and reblocked (500l PBS 1% BSA) for 15min
before the addition of the secondary antibody (HRP-conjugated
anti-mouse IgG (GE Healthcare)) diluted 1:2500 in 1% BSA in
PBS for 1 h. Following three further washes with PBS in HRP,
activity was determined using SigmaFast o-phenylenediamine
tablets (Sigma-Aldrich) according to the manufacturer’s in-
structions. Values were normalized toMyc-GLP-1R (for recep-
tor expression) or FLAG-RAMP2/CRLR (for RAMP expres-
sion) as 100% and cells transfected with empty vector as 0%.
cAMPAccumulation Assays—Transfected cells were washed
in PBS, resuspended in stimulation buffer (PBS containing 0.1%
BSA and 0.5 mM isobutylmethylxanthine), and seeded at 2000
cells/well in 96-well white OptiPlates. Ligands were added in
the range of 1 pM to 1 mM, and cAMP accumulation was mea-
sured after 30 min of stimulation using the LANCE cAMP
detection kit (PerkinElmer Life Sciences). Values were con-
verted to concentration using a cAMP standard curve per-
formed in parallel.
Competition-binding Assays—Homologous and heterolo-
gous competition-binding assays were performed on whole
cells transfected with GCGR in the absence and presence of
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RAMP2 using [125I]glucagon as the radioligand. Cells were
seeded into 6-well plates and grown to 80% confluence before
transfection with 1.5 g of plasmid DNA and incubated for a
further 24 h.Mediumwas then replacedwith freshDMEM, and
cells were transferred onto a 96-well plate coated with poly-D-
lysine and incubated for 24 h to achieve confluence prior to
assay. Binding was performed using an adaptation of the
method outlined previously (14) in a final volume of 180 l
with all components diluted in assay buffer (Krebs’ HEPES
buffer plus BSA, 10 mM HEPES, 4.2 mM NaHCO3, 11.7 mM
D-glucose, 1.18 mM MgSO47H2O, 1.18 mM KH2PO4, 4.69
mM KCl, 118 mM NaCl, and 1.3 mM CaCl22H2O 0.1% BSA
(w/v)). For the assay, cells were washed in assay buffer, 0.1
nM of radioligand and various concentrations of the peptides
were added, and the plate was incubated for 16 h at 4 °C.
Following washing with ice-cold assay buffer, 100 l of
NaOH (0.1 M) was added to each well, and the plate was
incubated for 5 min on ice. Cells were removed, and the plate
was washed with 100 l of HCl (0.1 M). Radioactivity was
determined in 2 ml of Safefluor scintillant (PerkinElmer Life
Sciences) using a liquid scintillation counter with a count
time of 3 min/sample. Values were corrected for nonspecific
binding as determined by the amount of radioligand
detected bound to cells not expressing GCGR.
Live Cell Imaging in HEK-293 Cells—Transfected cells were
seeded into 8-well microscope slides (Thistle Scientific, Glas-
gow, UK) and incubated (37 °C; 5%CO2, 95% air) for 25 h. Prior
to imaging, growthmediumwas replacedwith aHepes buffer as
detailed previously (15) prewarmed to 37 °C. Cells were viewed
on a Personal DeltaVision system (Applied Precision, Issaquah,
WA) equipped with a photometric CoolSNAP HQ camera
(Roper Scientific), and deconvolution was applied to images for
visual clarity as described previously (16).
Yeast Strain Construction and Assay—General yeast proce-
dures were performed as described previously (17, 18). Saccha-
romyces cerevisiae dual reporter strains expressing chimeras of
the yeast GPA1, residues 1–467 (GPA1/G), with the five
C-terminal amino acids of humanG protein corresponding to
Gs orGi3 (MMY84 andMMY89, respectively (19))were used
in this study because we have previously shown that both the
GLP-1 receptor and GCGR couple to these subunits (17)).
Mammalian GPCRs and RAMPs were introduced to the yeast
strains under the control of the GAPDH promoter using plas-
mids containing either ura3 (p426-GPD) or leu2 (p425-GPD).
Plasmidswere transformed in a 1:1 ratio to enable equal expres-
sion levels of both the RAMP and receptors. Transformation
was achieved using the lithium acetate/single-stranded DNA/
polyethylene glycol method as described previously (20). Posi-
tive transformants were selected and maintained on medium
lacking uracil and leucine. Receptor signaling was measured
using the yeast growth assay (21) adapted as described previ-
ously (17). Initially, cell growth was performed in SDURA
LEUmedium at 30 °C to select for only those cells expressing
both plasmids. Cells were then cultured to remove basal
activity in SDURALEUHIS medium overnight at 30 °C
and assayed using fluorescein-di--D-glucopyranoside-sup-
plemented medium in the presence of different concentrations
of ligand (0.01 nM to 100mM). Fluorescence was measured on a
TECAN Infinite M200 microplate reader (TECAN Ultra Evo-
lution, Reading, UK).
Scintillation Proximity Assay (SPA) for G Protein Activa-
tion—Receptor/G protein activation profiles were determined
using a scintillation proximity assay as described previously
(22). Cells were grown to confluence in DMEM with Glu-
taMAX, supplemented with 10% FCS and 1 penicillin/strep-
tomycin, in 5% CO2, 95% air at 37 °C. The cells were harvested
using trypsin/EDTA (Sigma-Aldrich), washed with PBS, and
resuspended in electroporation buffer (20 mM HEPES, 135 mM
KCl, 2 mM MgCl2, 2 mM ATP, 5 mM glutathione, 0.5% (v/v)
Ficoll 400 adjusted to pH 7.6 using KOH) at a concentration of
4 million cells in 4-mm gap electroporation cuvettes (York
Biosciences, UK) before the addition of the requiredDNA (5g
of receptor, 15 g of RAMP constructs). The cells were then
electroporated at 0.25 kV and 960 microfarads using a Gene
Pulser (Bio-Rad, Hemel Hempstead, UK) and then cultured for
48 h. The cells were then homogenized in ice-cold PBS using a
Dounce homogenizer and centrifuged at 300 g for 10 min at
4 °C in a final volume of 40ml. The supernatantwas collected in
a fresh tube and centrifuged at 50,000  g for 25 min at 4 °C.
The resulting pellet was resuspended in ice-cold SPA buffer (50
mM HEPES, 100 mM NaCl, 5 mM MgCl2, 0.5% (w/v) BSA, pH
7.4).
SPA Protocol—Concentration-response curves were con-
structed by incubating increasing agonist concentrations with
membranes (10g) prepared from cells transfectedwith recep-
tor and 0.1 M GDP in HEPES buffer (100 mM NaCl, 50 mM
HEPES, 5mMMgCl2, 0.5% (w/v) BSA fractionV, adjusted to pH
7.5 with KOH) in a total volume of 200 l in white OptiPlates
(PerkinElmer). The assay was initiated by the addition of 0.5 nM
[35S]GTPS and incubated for 1 h at 35 °C. The assay was ter-
minated by the addition of Nonidet P-40 at a final concentra-
tion of 0.3% (v/v) (Roche Diagnostics) and incubated at room
temperature for 30 min on a plate shaker. A 10-l aliquot of
anti-G protein antibody (Gs, sc-383; Gi, sc-262) at a concentra-
tion of 60g/l was then added, followed by a further 30min at
room temperature before the addition of 75 l of anti-rabbit
poly(vinyl toluene) SPA beads (PerkinElmer Life Sciences). The
plate was then sealed, incubated at 4 °C for 20 h, and spun at
1300 g for 10 min before reading in a TopCount scintillation
counter (PerkinElmer Life Sciences). Data are shown as
mean  S.E. for three independent experiments, each per-
formed in triplicate.
Data Analysis—Data were analyzed using Prism version 6.0e
(GraphPad Software, San Diego, CA). EC50 and Emax values
were obtained through fitting of a three-parameter logistic
equation. Relative efficacy (log ) and equilibrium dissociation
constants (log KA) were generated through use of an opera-
tional model for partial agonism (23). Fluorescent image anal-
ysis was performed using ImageJ version 1.46b using the
QUIMP plugin as described previously (17, 24). Statistical dif-
ferences were analyzed before data were normalized, using a
Student’s test or one-way analysis of variance (ANOVA) with
Bonferroni’s orDunnett’smultiple comparisons as appropriate,
and p 0.05 was considered significant.
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Results
RAMP2 Increases Glucagon Potency and Efficacy at the
GCGR—RAMPproteins require associationwith aGPCR, such
as the CLR, in the endoplasmic reticulum to enable efficient
translocation to the cell surface. Using an enzyme-linked
immunosorbent assay (ELISA), little or no cell surface expres-
sion of the RAMPs was seen when transfected alone into HEK-
293 cells. However, all three FLAG-tagged RAMPs were
detected at the cell surface, upon co-transfection with the CLR
(Fig. 1A). In contrast, the GLP-1 receptor was unable to trans-
locate any of the RAMPs to the cell surface. Upon co-transfec-
tion of each of the RAMPs with the GCGR, only RAMP2
resulted in detectable cell surface expression (Fig. 1). Similar
data were obtained using RAMP-GFP fusion constructs such
that co-expression of the CLR was required to enable observa-
tion of plasma membrane-associated RAMPs, and the GCGR
located only RAMP2 at the plasma membrane (Fig. 1B), dem-
onstrating a positive interaction between the GCGR and
RAMP2 in mammalian cells.
Like other family B GPCRs, upon ligand binding, the GCGR
preferentially activates Gs to stimulate adenylate cyclase and
generate cAMP. To investigate the effect of RAMP2 association
on GCGR pharmacology, we constructed cAMP concentra-
tion-response curves to glucagon in HEK-293 cells transiently
co-transfected with the GCGR and each of the individual
RAMPs. Co-expression of RAMP2 induced a 2-fold increase in
the maximal cAMP level (Emax) and a 10-fold increase in the
potency (EC50) of glucagon compared with the vector control
(Fig. 1C and Table 1). In contrast, co-expression of either
RAMP1 or RAMP3 did not influence the Emax or EC50 of glu-
cagon-mediated cAMP generation (Fig. 1B). In order to assess
whether agonist responses of the GCGR were influenced by
FIGURE 1. RAMP2 interacts with the GCGR. A, plasma membrane expression of FLAGRAMPs in cells transfected with vector control, CLR, GCGR, or GLP-1
receptor determined by ELISA. B, HEK-293 cells transfected with RAMP-GFP fusion constructs in the presence and absence of various GPCRs as indicated.
Arrows, plasmamembrane localization.C, cAMPaccumulationwasdetermined inHEK-293 cells transiently transfectedwith theGCGR in thepresenceof vector
control, RAMP1, RAMP2, or RAMP3 following 30-min stimulation with glucagon. D, plasma membrane expression of Myc-CLR or Myc-GLP-1R (as a positive
control) determined by ELISA in HEK-293 cells co-transfectedwith vector control or RAMP2. E, cAMP accumulation, measured following 30-min stimulation of
HEK-293 cells with CGRP or AM expressing CLR in the presence of vector control, RAMP1, or RAMP2. All values are the mean of at least five independent
experiments S.E. (error bars). Statistical significance was determined using one-way ANOVA with Dunnett’s post-test, where each data set was compared
with vector control (***, p 0.001; ****, p 0.0001).
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endogenously expressed RAMPs in HEK-293 cells, we uti-
lized the absolute requirement of the CLR receptor to inter-
act with a RAMP to produce a functional receptor at the
plasma membrane (11). In the absence of co-transfected
RAMPs, we were unable to detect the CLR at the cell surface
by ELISA using a Myc tag (Fig. 1D). Furthermore, cAMP
accumulation was not observed following stimulation with
either CGRP or AM (Fig. 1E). These data indicate that there
is insufficient endogenous RAMP expression in HEK-293
cells to interact with the CLR, thus effectively providing a
null background in which to study the effect of RAMP2 asso-
ciation with the GCGR.
Changes in GCGR Pharmacology Are Not Due to an Increase
in Cell Surface Expression or Ligand Binding Affinity—The cell
surface expression and ligand binding properties of several
family B receptors (10, 11) are enhanced through association
with RAMPs. We used both quantitative image analysis of
C-terminal receptor-fluorescent protein fusion constructs (Fig.
2A) and cell surface ELISAs of Myc-tagged receptors (Fig. 2B)
to determine the effect of RAMP2 on receptor trafficking. In
contrast to the CLR, which was only observed (Fig. 2A, arrows)
or detected (Fig. 2B) at the plasma membrane when co-trans-
fected with a RAMP, no change in the level of GCGR at the cell
surface could be determined. Increases in the amount of
RAMP2 relative to GCGR transfected into HEK-293 cells
resulted in an elevated level of FLAG-tagged RAMP2 at the
plasmamembrane but did not enhance the level ofMyc-GCGR
detected (Fig. 2C), although a RAMP2-dependent increase in
both potency and Emax was observed as measured through glu-
cagon-stimulated cAMP (Fig. 2D). Further, a homologous com-
petition-binding assay on cells expressing the GCGR in the
presence and absence of RAMP2 revealed no change in recep-
tor affinity for glucagon (Fig. 2E). These data suggest that the
elevated cAMP production and increased glucagon potency
observed upon association of the GCGR with RAMP2 (Fig. 1B)
do not arise due to changes in ligand binding affinities or
enhanced cell surface expression.
Modulation of GCGR Pharmacology by RAMP2 Is G
Protein-dependent—Intracellular levels of cAMP can be regu-
lated by GPCRs both positively (most notably via activation of
Gs) and negatively (via stimulation of Gi). The GCGR cou-
ples to both of these competing G protein subunits in mamma-
lian cells (25). Further, expression of the GCGR in a yeast sys-
tem containing chimeric (yeast-human) G proteins that allows
the isolation of individual GPCR-G protein interactions has
revealed functional coupling of the receptor to both Gs and
Gi subunits (17). The chimeric G proteins in this S. cerevisiae
system allow the coupling of human GPCRs to the endogenous
yeast-mating pathway. This pathway has been modified to
include a growth reporter and thereby provides the opportunity
to analyze the proportion of a receptor’s response attributable
to individual pathways (18, 26, 27) by assessing the extent of
reporter activity following stimulation with a range of ligands.
Co-expression of RAMP2 (but not RAMP1) with the GCGR
increased the potency andmaximal response to glucagon when
the receptor coupled to the chimeric protein of the yeast
-subunit and mammalian Gs (GPA1/Gs) (Fig. 3A). How-
ever, a reduction in response was observed in strains ex-
pressing GPA1/Gi (Fig. 3B and Table 2). Using an SPA, we
determined the activation of specific G proteins in trans-
fected mammalian cells (Fig. 3, C andD). RAMP2 co-expres-
sion resulted in no change in glucagon-stimulated Gs
activation; however, the maximal level of Gi activation
achieved was reduced 2-fold (Table 2). These results demon-
strate that RAMP2 expression in mammalian cells results in
a change to the GCGR-mediated activation of individual G
proteins similar to that seen in the yeast assay. Taken
together, these data demonstrate that the ability of RAMP2
to alter glucagon-mediated responses at the GCGR is G
protein-dependent; a RAMP2 interaction with GCGR ap-
pears to specifically reduce Gi activation.
Because Gs and Gi have opposing influence on adenylate
cyclase activity in mammalian cells, these observations could
explain the RAMP2-dependent elevation in glucagon-induced
cAMP generation in HEK-293 cells (Fig. 2B). RAMP2 may
selectively reduce coupling of theGCGR toGi, thereby leaving
activation of Gs unopposed. To assess this, we pretreated
HEK-293 cells with PTX to prevent receptor-mediated Gi
activation (28). In cells treated with PTX, the potency and
Emax of glucagon-stimulated cAMP generation by the GCGR
were increased similar to those in cells co-expressing
RAMP2 (but not PTX-treated) (Fig. 3E). PTX treatment had
no effect on the potency or maximal response in cells co-ex-
pressing the GCGR and RAMP2 (Fig. 3E and Table 1). These
data suggest that RAMP2 uncouples the GCGR from Gi;
this is entirely consistent with the data from the yeast cell
and SPA assays.
RAMP2Modulates GCGR Pharmacology in a Ligand-depen-
dent Manner—To further investigate the effect of RAMP2
onGCGRpharmacology, we next analyzed changes in signaling
in response to the related glucagon ligand, oxyntomodulin. In
HEK-293 cells, challenge of the GCGR with oxyntomodulin
resulted in a concentration-dependent increase in cAMP but
withweaker potency than glucagon (Fig. 4A andTable 3). How-
ever, similar to the effects observed with glucagon, RAMP2
co-transfection increased both the potency and maximal
cAMP production without affecting the binding affinity of
oxyntomodulin (Fig. 4B). In S. cerevisiae, although the co-
expression of RAMP2 potentiated the response to oxynto-
modulin in the GPA1/Gs yeast strain, it did not affect
responses in the GPA1/Gi strain (Fig. 4, C and D). This is in
contrast to the inhibitory impact of RAMP2 association on
glucagon-mediated GCGR responses in the GPA1/Gi-ex-
TABLE 1
Potency (pEC5) and maximal response (Emax) to glucagon in cAMP
assay performed on HEK-293 cells expressing the GCGR with or with-
out the indicated RAMPs
Values were generated through fitting of a three-parameter logistic equation and
represent the mean  S.E. from 5 independent experimental repeats. Statistical
significance compared with vectorPTX (RAMP2PTX for z) (***, p 0.001) was
determined by one-way ANOVA with Dunnett’s post-test.
a The negative logarithm of the agonist concentration required to generate half
the maximal response.
b The maximal response to the ligand expressed as a percentage of that obtained
in the absence of pertussis toxin in cells expressing empty vector control.
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pressing yeast. Furthermore, PTX treatment of HEK-293
cells expressing the GCGR had no effect on the potency of
oxyntomodulin-mediated cAMP responses, although there
was a small increase in Emax. Intriguingly, this increase
occurred independently of RAMP2 expression (Fig. 4A). In
RAMP2-expressing cells, there was, however, a small
decrease in the potency of oxyntomodulin-induced cAMP
production following incubation with PTX. These data indi-
FIGURE 2. Co-expression of RAMP2 does not affect cell surface expression of the GCGR or glucagon binding. A (i), HEK-293 cells were transfected with
fluorescently labeled receptors in the presence or absence of RAMP2. Arrows, plasma membrane localization. A (ii), the percentage of plasma membrane
fluorescencewas quantified using theQUIMP plugin for ImageJ for at least 20 cells in each population, andmean data S.E. (error bars) are represented in the
bar chart. B, plasma membrane expression of Myc-tagged-GCGR in cells transfected with vector control, RAMP1, or RAMP2 determined by ELISA. C, plasma
membrane expression of FLAG-tagged RAMP2 (i) and Myc-tagged-GCGR (ii) determined by ELISA in HEK-293 cells transfected with the indicated ratios of
FLAG-tagged RAMP2 to Myc-tagged GCGR. D, HEK-293 cells expressing the GCGR and the indicated ratios of RAMP2 were assayed for cAMP accumulation
following 30-min stimulation with glucagon. E, whole cell competition binding analysis of glucagon at the GCGRwith [125I]glucagon tracer in the presence or
absence of RAMP2. Valueswere corrected for nonspecific binding (NSB) and normalized tomaximum [125I]glucagonbinding. All values are themeanof at least
five independent experiments  S.E. Statistical significance was determined using one-way ANOVA with Dunnett’s post-test where each data set was
compared with vector control (**, p 0.01; ***, p 0.001; ****, p 0.0001).
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cate that the effect of RAMP2 on the GCGR Gi response is
sensitive to the activating ligand.
GLP-1 Is a Partial Agonist at the GCGR in the Absence of
RAMP2—Tissue-specific processing of pro-glucagon produces
several peptides, including oxyntomodulin, glucagon, and
GLP-1 (29), which, in itsmajor post-prandial active form (GLP-
1(7–36) amide, hereafter referred to as GLP-1), is considered to
act in opposition to glucagon by stimulating insulin secretion.
Although oxyntomodulin and glucagon can also stimulate the
GLP-1 receptor (17, 29, 30), a limited number of studies have
suggested that GLP-1 cannot bind to the GCGR (31, 32). Given
that similarities between both ligands (Fig. 5A) and receptors
(33) of this family are comparable with or greater than those in
other systems (e.g. the calcitonin or parathyroid hormone fam-
ilies) that show common binding properties, we wished to
FIGURE3.RAMP2-mediatedmodulationof theGCGR isGprotein-dependent.A andB, glucagon concentration-response curves in yeast strains containing
either GPA1/Gs (A) or GPA1/Gi (B) chimeras expressing the GCGR in the presence of a vector control, RAMP1, or RAMP2. Activation of the reporter genewas
calculated as a percentage of the maximum response observed in the absence of RAMP2. C and D, SPAs to determine Gs (C) and Gi (D) activation upon
stimulation of cell membranes, containing the GCGR in the presence or absence of RAMP2, with increasing concentrations of glucagon. E, HEK-293 cells
containing the GCGR and RAMP2 or a vector control were incubated with 200 ng/ml PTX or a vehicle control for 16 h before stimulation with glucagon and
determination of cAMP accumulation. All values are the mean of at least three independent experiments S.E. (error bars).
TABLE 2
Potency (pEC50) andmaximal response (Emax) toglucagonat theGCGR
expressedwith orwithout RAMP2measured in yeast cell and scintilla-
tion proximity assays
Values were generated through fitting of a three-parameter logistic equation and
represent the mean S.E. from at least 3 independent experimental repeats. Statis-
tical significance compared with vector (**, p 0.01; ***, p 0.001) was determined
by one-way ANOVA with Dunnett’s post-test.
a The negative logarithm of the agonist concentration required to generate half
the maximal response.
b The maximal response to the ligand expressed as a percentage of that obtained
in the absence of RAMP expression.
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determine whether a reciprocal activation of the GCGR by
GLP-1 was possible. Initially, we used yeast strains expressing
the GCGR and either the GPA1/Gs or GPA1/Gi chimera,
and we determined that GLP-1 was able to weakly activate the
GCGR, thereby acting as a partial agonist compared with glu-
cagon (Fig. 5, B and C, and Tables 4 and 5). The observed dif-
ference in potencies betweenGLP-1 and glucagon is unlikely to
reflect the ability of each peptide to penetrate the yeast cell wall
because alternative rank orders of activity have been reported
for these ligands at the GLP-1 receptor (17).
Due to its role in insulin secretion, the GLP-1 receptor has
received significant attention as a possible therapeutic target
for treating type 2 diabetes, resulting in the approval of three
peptide analogues of GLP-1 (liraglutide, exenatide, and lixisen-
atide) for clinical use. These mimetics have been designed to
activate the GLP-1 receptor but also to resist proteolytic degra-
dation, particularly by dipeptidyl peptidase IV, thereby consid-
erably enhancing their plasma half-life beyond the 1–2 min of
natural GLP-1. Significantly, among the clinically approved
drugs tested here, only liraglutide (with 97% homology to
GLP-1) stimulated a response in GCGR-expressing yeast
strains (Fig. 5, B and C, and Tables 4 and 5). Similar to GLP-1,
liraglutide displayed partial agonism at the GCGR with a
reduced potency compared with glucagon. Intriguingly, co-ex-
pression of RAMP2 prevented both peptides from activating
the GCGR in the yeast strains (Fig. 5, B and C). This effect was
specific to the RAMP2-GCGR receptor interaction because co-
expression of RAMP2with theGLP-1 receptor had no effect on
receptor pharmacology in either yeast or cAMP assays (Fig. 6).
RAMP2 Expression Prevents GLP-1 Binding to the GCGR—
Having observed a RAMP2-specific modulation of GLP-1-me-
diated activation of the GCGR in yeast cells, we next examined
these interactions inmammalian cells. Both GLP-1 and liraglu-
tide were partial agonists of cAMP generation compared with
glucagon at the GCGR (Fig. 7, A and B, and Table 3). This
agonism by the GLP-1 receptor ligands was abolished upon
co-transfection of RAMP2. These effects were specific to a
RAMP2-GCGR interaction; RAMP2 did not affect GLP-1-me-
diated cAMP generation by the GLP-1 receptor in HEK-293
cells (Fig. 6C). Further, the addition of aGCGR antagonist (des-
His1-[Glu9]glucagon(1–29) amide) inhibited GLP-1 and lira-
glutide signaling through the GCGR (Fig. 7, A and B). Finally,
ligand binding assays revealed that, contrary to previous
reports, GLP-1 and the related mimetic, liraglutide, bound to
the GCGR in competition with glucagon. Significantly, both
GLP-1 and liraglutide failed to bind to theGCGR upon RAMP2
co-transfection (Fig. 7C). Titration experiments to increase the
concentration of RAMP2 revealed that the GLP-1-mediated
GCGR cAMP response is extremely sensitive to the presence of
RAMP2 (Fig. 7D). These data demonstrate that RAMP2 specif-
ically regulates binding and thereby signal transduction of
GLP-1 ligands at the GCGR. Previous work on the ability of
GLP-1 receptor ligands to activate the GCGR has not consid-
ered the influence of RAMPs,whichmay have obscured such an
interaction.
Discussion
RAMPs have long been known to modify the pharmacology
of family B GPCRs, altering the efficacy and potency of ligands
FIGURE 4. RAMP2-mediated modulation of the GCGR is ligand-depen-
dent. A, HEK-293 cells co-transfected with the GCGR and either a vector con-
trol or RAMP2were incubatedwith 200 ng/ml PTX (or vehicle control) for 16 h
before stimulation with oxyntomodulin for 30 min and measurement of
cAMP accumulation. B, whole cell competition binding analysis of oxynto-
modulinwith [125I]glucagon tracer at the GCGR in the presence or absence of
RAMP2. Values were corrected for nonspecific binding (NSB) and normalized
to maximum [125I]glucagon binding. GPA1/Gs (C) or GPA1/Gi (D) chimeric
yeast strains transformedwith theGCGRandeither a vector control or RAMP2
were stimulated with oxyntomodulin, and receptor activity was determined.
All values are expressed as a percentage of themaximum response observed
to glucagon in the absence of RAMP2 and are the mean of at least five inde-
pendent experiments S.E. (error bars).
TABLE 3
Potency (pEC50), affinity (pKa), and coupling efficacy (log ) values for
various glucagon receptor agonists measured in HEK-293 cells
expressing the GCGR with or without RAMP2 using a cAMP assay
All values are mean  S.E. of five independent experimental repeats. Statistical
significance compared with vector (*, p  0.05, ***, p  0.001) was determined by
one-way ANOVA with Dunnett’s post-test. N.R, no response.
a The negative logarithm of the agonist concentration required to produce a half-
maximal response.
b The maximal response to the ligand expressed as a percentage of that obtained
to glucagon in the absence of RAMP co-transfection.
c The negative logarithm of the relative equilibrium disassociation constant for
each ligand generated through use of the operational model for partial agonism
relative to glucagon.
d  is the coupling efficiency parameter, generated by comparison with the natural
ligand, glucagon, using the operational model for partial agonism.
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FIGURE 5. GLP-1 receptor agonists are functional at the GCGR in the absence of RAMP2. A, sequences of the various peptide ligands used in this
study aligned to the natural agonist, glucagon. Amino acids differing from those in glucagon are highlighted in gray. Red boxes highlight partially
conserved hydrophobic regions required for GCGR binding (31). GPA1/Gs (B) or GPA1/Gi (C) chimera yeast strains containing GCGR in the presence
or absence of RAMP2 were used to determine reporter gene activity following stimulation with various GLP-1 receptor agonists. All data are expressed
as a percentage of themaximum response observed to glucagon in the absence of RAMP2 and are themean of at least five independent experiments
S.E. (error bars).
TABLE 4
Potency (pEC50), affinity (pKa), and coupling efficacy (log ) values for
variousglucagon receptor agonistsmeasured in yeast strains contain-
ing the GPA1/Gs chimera and expressing the GCGR with or without
RAMP2
All values are mean  S.E. of five independent experimental repeats. Statistical
significance compared with vector (***, p  0.001) was determined by one-way
ANOVA with Dunnett’s post-test. N.R, no response.
a The negative logarithm of the agonist concentration required to produce a half-
maximal response.
b The maximal response to the ligand expressed as a percentage of that obtained
to glucagon in the absence of RAMP co-expression.
c The negative logarithm of the relative equilibrium disassociation constant for
each ligand generated through use of the operational model for partial agonism
relative to glucagon.
d  is the coupling efficiency parameter, generated by comparison with the natural
ligand, glucagon, using the operational model for partial agonism.
TABLE 5
Potency (pEC50), affinity (pKa), and coupling efficacy (log ) values for
variousglucagon receptor agonistsmeasured in yeast strains contain-
ing the GPA1/Gi chimera and expressing the GCGR with or without
RAMP2
All values are mean  S.E. of five independent experimental repeats. N.R, no
response; N.D, not determined.
a The negative logarithm of the agonist concentration required to produce a half-
maximal response.
b The maximal response to the ligand expressed as a percentage of that obtained
to glucagon in the absence of RAMP co-expression.
c The negative logarithm of the relative equilibrium disassociation constant for
each ligand generated through use of the operational model for partial agonism
relative to glucagon.
d  is the coupling efficiency parameter, generated by comparison with the natural
ligand, glucagon, using the operational model for partial agonism.
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and changing their ligand preference entirely, thereby having the
ability to create distinct receptors (11–13). Although the interac-
tion between RAMP2 and the GCGRwas identified over 10 years
ago (9), this study is the first to investigate the pharmacological
consequences of the association. Here we have shown, using a
combination of bothmammalian and yeast cell assays, that co-ex-
pressionwithRAMP2 causes amarked change inGCGRpharma-
cology through alterations in G protein coupling that are also de-
pendent upon the activating ligand.
One particular strength of our approach, using both the
mammalian and yeast systems, is that we have identified subtle
differences in signaling that might not have been apparent
through the use of a single assay. For example, inHEK-293 cells,
the impact of RAMP2 on cAMP responses to glucagon and
oxyntomodulin was essentially the same, with a potentiation in
cAMP accumulation in both cases (Figs. 3 and 4). However, in
the yeast assay, in which the activation of individual (compet-
ing) G protein pathways can be assessed, there were clear li-
gand-dependent differences in the impact of RAMP2 on signal-
ing by the GCGR. In the case of glucagon, RAMP2 potentiated
the response mediated through the GPA1/Gs chimera (Fig.
3A) but reduced activation through the GPA1/Gi chimera
(Fig. 3B). In contrast, RAMP2 modulation of the oxyntomodu-
lin response only occurred through the GPA1/Gs chimera
(Fig. 4, A and B).
In HEK-293 cells, co-expression of RAMP2 with the GCGR
resulted in potentiation of both glucagon- and oxyntomodulin-
stimulated cAMP. However, the GCGR couples to both stimu-
latory (Gs) and inhibitory (Gi) G proteins that combined reg-
ulate cAMP production following receptor stimulation (25).
Through a variety of different techniques, we demonstrated
that themechanism bywhich the RAMP2 achieved this affect is
both ligand- andGprotein-specific. The data suggest thatwhen
glucagon is used as the ligand, the presence of RAMP2 reduces
the Gi component. In contrast, the affect on the oxyntomodu-
lin response occurs through the potentiation of the Gs activity
when measured in the yeast assay. This is broadly supported in
the cAMP response, with an increase in Emax being observed
following PTX treatment of HEK-293 cells. However, PTX
appeared to reduce the affect of RAMP2 on the potency of
oxyntomodulin. This possibly indicates the presence of another
competing G protein-mediated pathway (e.g. Gq (7) which,
through the promotion of protein kinase C activation has been
reported to affect PTX-sensitivity of other Gs/Gi-coupled
family B GPCRs (34)). The elevation of intracellular calcium by
GCGR activation has been relatively well described and has
been demonstrated to occur in transfected HEK-293 cells via
both Gi and Gq-mediated pathways (7). It is somewhat sur-
prising that little attention has been given to the ability of the
GCGR to signal via Gi, and our data suggest that further work
is required to fully elucidate the physiological role of the Gi
coupling.
The GCGR is one of a number of receptors that regulate
glucose homeostasis within the body (6). Its primary role is to
promote the release of glucose from the liver to maintain suit-
able levels of blood glucose. The opposing role is played by the
FIGURE 6.RAMP2 co-expression does not affect GLP-1 receptor pharmacology. The GLP-1 receptor was expressed in the presence and absence of RAMP2
in yeast strains containing GPA1/Gs (A) or GPA1/Gi (B) chimeras, and reporter gene activity was determined following stimulation with the natural agonist,
GLP-1.C, cAMPaccumulationwasmeasured following30-min stimulationof untransfectedHEK-293 cells and those expressing theGLP-1 receptor in either the
presenceor absenceof RAMP2. All data are expressed as apercentageof themaximumresponseobserved toGLP-1 in the absenceof RAMP2andare themean
of at least five independent experiments S.E. (error bars).
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relatedGLP-1 receptor,which, through anumber of actions but
primarily through the induction of insulin release, promotes
the lowering of blood glucose levels following food ingestion.
We (17) and others (30, 31) have previously reported the ability
of theGCGR ligands to activate theGLP-1 receptor. Significant
findings of the present study are the potential for GLP-1 recep-
tor ligands to bind and stimulate the GCGR and the ability of
RAMP2 to inhibit this. Both GLP-1(7–36) amide, the major
active post-prandial circulating form of GLP-1, and the syn-
thetic, clinically used peptide liraglutide displayed partial ago-
nism at the GCGR. Intriguingly, neither lixisenatide nor
exenatide, both long acting, clinically used GLP-1 mimetics,
were able to stimulate theGCGR. Significantly, activation of the
GCGR by the GLP-1 receptor ligands was abolished upon co-
expression of RAMP2, and this was independent of the G pro-
tein present. These results suggest that unlike glucagon and
oxyntomodulin, RAMP2 exerts its effects on GLP-1-mediated
GCGR activation via preventing ligand binding. Given the dif-
ferential expression of RAMP2 across mammalian cell lines,
these results offer a possible explanation for previous studies
that have been unable to observe GLP-1 (and liraglutide) activ-
ity at the GCGR (31–32). Furthermore, given that RAMPs are
expressed across many different tissues (11), including many
where GCGR activity has also been reported (36–37), our
resultsmay also provide insight into physiological observations.
For example, RAMP2 expression in the heart has been shown to
be significantly up-regulated in mouse models of heart failure
(38). Given the observations by Ban et al. (39) that GLP-1 has a
cardioprotective role acting via a receptor other than GLP-1R
and our results demonstrating that RAMP2 prevents GLP-1-
GCGR activity, it would be interesting to determine whether
RAMP2 interacts with theGCGR to alter signal transduction in
cardiomyocytes and whether this interaction is perhaps pre-
venting the actions of GLP-1, leading to heart failure. However,
FIGURE 7. GLP-1 specifically binds the GCGR only in the absence of RAMP2. cAMP accumulation was measured in HEK-293 cells co-transfected with the
GCGR and either a vector control or RAMP2 following stimulation with GLP-1 (A) and liraglutide (B) in the presence and absence of a GCGR antagonist,
des-His1-[Glu9]glucagon(1–29) amide. C, whole cell competition binding analysis of GLP-1 and liraglutide with [125I]glucagon tracer at the GCGR in the
presence or absence of RAMP2. Values were corrected for nonspecific binding (NSB) and normalized to maximum [125I]glucagon binding. D, HEK-293 cells
expressing the GCGR and the indicated ratios of RAMP2were assayed for cAMP accumulation following 30-min stimulationwith GLP-1. All data are expressed
as a percentage of the maximum response observed to glucagon in the absence of RAMP2 and are the mean of at least five independent experiments S.E.
(error bars).
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no studies to date have simultaneously assessed the cellular
content of both RAMP2 and GCGR.
Interestingly, the binding experiments presented in this study
suggest that GLP-1 and liraglutide display a higher affinity for the
GCGRthanthenativepeptide.However, thisdidnot translate into
an increase in potency relative to glucagon when measured as
cAMP production. It is possible that the high affinity binding of
these ligands promotes the activation of alternative GCGR-medi-
ated pathways with greater potency than that seen for cAMP, but
further investigation is required to determinewhether GLP-1 and
liraglutide are truly biased ligands at the GCGR.
Indeed, other receptors for GLP-1R ligands have been sug-
gested (39, 40). In such reports, some effects of GLP-1 ligands
have been observed in the absence of the GLP-1 receptor
through the use of either specific antagonists or knock-out ani-
mals. Given the results presented here and the tissue distribu-
tion ofGCGR expression (36, 37), we suggest that some of these
effects may bemediated via the GCGR. However, in some assay
systems, the ability of GLP-1 receptor ligands to cross-react
with the GCGR may have been missed due the presence of
RAMP2. These data highlight the need to consider GCGR and
RAMP2 expression when designing novel therapies to prevent
unwanted activity. Hybrid peptides that modulate both the
GCGR and GLP-1 receptor in different ways have also been
suggested as potentially beneficial (41). Previously, it has been
thought that such a compound would have to display agonist
activity at the GLP-1 receptor while antagonizing the GCGR.
However, our data reveal the possibility of using an agonist to
both receptors that is biased to different downstreampathways.
For example, a ligand that stimulates the GLP-1 receptor-Gs
andGCGR-Gi pathwayswould have an effect similar to that of
an agonist-antagonist combination. Due to the observed ligand
and RAMP-engendered signaling bias observed, our data offer
new mechanistic information that could be useful in the devel-
opment of such co-agonists.
Structure-activity relationship studies for the GLP-1 recep-
tor have suggested various important residues required in both
the receptor and ligand for binding and activation (42).Many of
these reported residues are also found within the TM regions
of the GCGR and are required for interaction of theN terminus
of the ligand (which is relatively well conserved across the
ligands used in this study (Fig. 5A)). Given that RAMPs have
been shown to modify the ligand-GPCR interaction for other
receptors (12, 43), it is possible that the formation of a RAMP2-
GCGRcomplex subtly changes the arrangement of key residues
involved in GLP-1 binding, thereby preventing its interaction.
It would therefore be interesting to observe how the presence of
RAMP2 alters the residue arrangement of the recently pub-
lished crystal structure of the GCGR (44). Initial homology
models, built upon the assumption that GLP-1 binds in a simi-
lar mode to the GCGR extracellular domain as it does to the
GLP-1 receptor suggest that the interaction of RAMP2 with
GCGR may block GLP-1 binding. Loop 5 of the GCGR extra-
cellular domain is shorter than its GLP-1R counterpart, having
an unusual type I turn (45) that creates a more constrained
environment for theGLP-1C terminus. If RAMP2bound to the
GCGR in a way similar to that of the CLR (46) then the addi-
tional steric constraints in the vicinity of the GLP-1 C terminus
may discourage binding. It should be noted that these conclu-
sions are speculative and require further in depth analysis
before definitive conclusions can be drawn. The two hydropho-
bic regions foundwithin glucagon and oxyntomodulin required
for binding to the extracellular domain of the receptor and
forming interactions with the extracellular loop 1 (33) are par-
tially conserved in the C termini of both GLP-1 and liraglutide
but not in exenatide and lixisenatide (boxed regions in Fig. 5A).
These observations provide a possible explanation for the lack
of activity at the GCGR displayed by the latter two ligands.
The idea that ligands can influence pathway selectivity of
GPCRs, termed biased agonism, has been suggested for many
years (8) and is supported by the observed structural links
between the ligand-binding pocket, via TM domains, to the
intracellular G protein binding site (47, 48). Furthermore, it has
been shown that different G protein subunits can influence the
structure adopted by a GPCR, thereby influencing ligand bind-
ing (10). Additionally, Udawela et al. (49) have demonstrated
that the different domains of RAMP proteins enable them to
influence both ligand andG protein selectivity of GPCRs. Stud-
ies using the calcitonin receptor have revealed that RAMP
modulation of ligand potencies can be pathway-specific. These
studies show that RAMP expression has a greater affect on
amylin potency when cAMP accumulation is used as ameasure
of receptor activity compared with when calcium mobilization
is monitored demonstrating that RAMPs may have a direct
effect on G protein coupling efficiency (13). These reports,
combined with our own observations, suggest that there is a
complex interplay between ligand, RAMP, receptor, andG pro-
tein that combine to bring about signal transduction, with each
component being able to affect the binding or activity of
another. Although theGCGR is expressed in the liver, where its
main biological function is to counterbalance insulin actions, it
is also expressed in a vast array of other tissues (50), including
the lung, pancreas, and kidney. Interestingly, in mouse studies,
varying levels of RAMP2 mRNA have been reported in these
tissues (35). RAMP2 expression was higher in the pancreas,
where GCGR stimulation enhances glucagon secretion (50),
than in the liver, where receptor activity stimulates glucose
release (6). Understanding how the GCGR signals within each
of these tissues will enable the design of biased drugs that spe-
cifically engage the most therapeutically beneficial pathways
and reduce unwanted side effects. Our data, which reveal a role
for RAMP2 in determining both ligand selectivity and the
downstream signaling pathways of the GCGR, highlight the
critical need to consider all components present in target cells
when designing new therapeutics.
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